Effects of Finasteride on Serum Prostate-Specific Antigen
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Androgenetic Alopecia
Intervention: MK0906, finasteride / Duration of Treatment : 48 Weeks (Drug); Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A clinical study to collect additional data in order to characterize the reduction in PSA
with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the
ages of 40 to 60 years.
Clinical Details
Official title: A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Primary outcome: Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment
Secondary outcome: Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug
Eligibility
Minimum age: 40 Years.
Maximum age: 60 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria :
- Men 40 to 60 years of age, and in good general physical and mental health, with
androgenetic alopecia
Exclusion Criteria :
- History of previous bladder surgery, acute urinary retention, urethral strictures,
repeated urethral catheterizations, repeated urinary tract infections, or active
urinary tract infections
- History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any
component of finasteride.
Locations and Contacts
Additional Information
Starting date: March 1998
Last updated: November 2, 2006
|
